KNSA — Kiniksa Pharmaceuticals International, plc
No mentions collected in the last 24 hours.
KNSA — 오늘 왜 언급됐나 (2026-10-28)
- 킨키사 파마슈티컬스는 2026년 3분기 매출이 58% 증가한 2억 8,600만 달러를 기록했습니다.
Why people talked about KNSA
- Kiniksa Pharmaceuticals reported Q3 2026 revenue of $286 million, marking a 58% increase.
- The company raised its 2026 guidance to $1.045–1.050 billion, the third increase this year.
- Net income reached $47.3 million with $568.8 million in cash, while PASTORALE data is expected in 2H 2027.